Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index; 8 of the 28 sources its claims cite were checked for support.

Identification and characterization of Cardiac Glycosides as senolytic compounds

Open access
Triana-Martínez, Francisco, Picallos-Rabina, Pilar, Da Silva-Álvarez, Sabela, Pietrocola, Federico, Llanos, Susana, Rodilla, Verónica, Soprano, Enrica, Pedrosa, Pablo, Ferreirós, Alba, Barradas, Marta, Hernández-González, Fernanda, Lalinde, Marta, Prats, Neus, Bernadó, Cristina, González, Patricia, Gómez, María, Ikonomopoulou, Maria P., Fernández-Marcos, Pablo J., García-Caballero, Tomás, del Pino, Pablo, Arribas, Joaquín, Vidal, Anxo, González-Barcia, Miguel, Serrano, Manuel, Loza, María I., Domínguez, Eduardo, Collado, Manuel · 2019 · Nature Communications

Abstract

Compounds with specific cytotoxic activity in senescent cells, or senolytics, support the causal involvement of senescence in aging and offer therapeutic interventions. Here we report the identification of Cardiac Glycosides (CGs) as a family of compounds with senolytic activity. CGs, by targeting the Na+/K+ATPase pump, cause a disbalanced electrochemical gradient within the cell causing depolarization and acidification. Senescent cells present a slightly depolarized plasma membrane and higher concentrations of H+, making them more susceptible to the action of CGs. These vulnerabilities can be exploited for therapeutic purposes as evidenced by the in vivo eradication of tumors xenografted in mice after treatment with the combination of a senogenic and a senolytic drug. The senolytic effect of CGs is also effective in the elimination of senescence-induced lung fibrosis. This experimental approach allows the identification of compounds with senolytic activity that could potentially be used to develop effective treatments against age-related diseases.

Overview

CoChat Summary

TL;DR

Cardiac glycosides (CGs), identified through high-throughput screens, selectively kill senescent cells by targeting the Na+/K+ATPase and exploiting senescent-cell depolarization and acidification. Digoxin combined with senescence-inducing chemotherapy reduced tumors in mice and alleviated senescence-induced lung fibrosis.

Key findings

  • Screening the 1,280-compound Prestwick library in mixed proliferating/senescent A549 cells yielded 9 hits, including Proscillaridin A; CGs showed nanomolar IC50 values and senolytic indexes from 3.33 (Ouabain in A549) to 301 (Proscillaridin in BJ fibroblasts).
  • Independent screens of 480 GPNCL natural compounds and 502 SCREEN-WELL natural products in Palbociclib-induced SK-MEL-103 melanoma cells identified six positives, all CGs: Ouabain, Bufalin, Cinobufagin, Peruvocide, Digitoxin, and Convallatoxin; a 200-venom screen found senolytic activity only in toad-derived venoms.
  • CG senolysis occurred by apoptosis, with increased Annexin V and active Caspase-3 and protection by pan-caspase inhibitor Z-VAD-FMK; mechanism involved Na+/K+ATPase alpha-subunit inhibition, plasma-membrane depolarization, and intracellular H+ increase, with KCl rescue and NHE1/SLC9A1 overexpression protecting senescent cells.
  • In vivo, Gemcitabine (25 mg/kg) plus Digoxin (2 mg/kg) caused robust A549 xenograft regression, with most tumors disappearing after three weeks; in PDX375, Digoxin plus senescence-inducing Doxorubicin (10 mg/kg) significantly reduced tumor volume, while non-senescence-inducing Doxorubicin (2 mg/kg) did not. Digoxin also reduced CDKN2A expression and fibrosis in a lung model induced by senescent human IMR90 cells.

Methods

  • Cell-based high-throughput screening: A549-GFP and A549-RFP cells mixed 1:3, senescence induced with Bleomycin (20 μM, 5 days), plated in 384-well plates, treated with libraries at 10 μM, and counted with Operetta; Navitoclax (1 μM) was positive control. A second screen used SK-MEL-103 cells induced with Palbociclib (5 μM, 7 days) against natural-product and venom libraries.
  • In vivo models: subcutaneous A549-luc xenografts in immunodeficient nude mice treated with Gemcitabine, Digoxin, or both; PDX375 breast tumor xenografts treated with Doxorubicin and/or Digoxin; lung fibrosis induced by intratracheal instillation of proliferating or gamma-irradiated senescent IMR90 cells followed by Digoxin or vehicle.
  • Main analyses: IC50 curves, flow cytometry for Annexin V and active Caspase-3, membrane potential and pH probes, Q-RT-PCR, senescence-associated β-galactosidase staining, immunohistochemistry for Ki67 and p21, Masson Trichrome and hydroxyproline for fibrosis, and two-tailed Student’s t-test or ANOVA with Tukey test.

Limitations

  • The paper states that Digoxin has a narrow therapeutic window, and although senolytic doses fell within the therapeutic range for some cell types and senescence inducers, this may not hold for all cell types, requiring individual assessment.
  • The paper states that the known insensitivity of rodents to CGs precluded the use of immunocompetent mouse models of cancer development.
  • Evident from the text: in vivo experiments were not repeated like in vitro experiments, sample size was not pre-determined, and the mechanism is not fully resolved because ATP1A1 knockdown did not cause cell death and other Na+/K+ATPase alpha subunits may be involved.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41467-019-12888-x

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 High-throughput screenings of senolytic compounds. a Schematic diagram of the experimental system used to screen compounds for potential senolytic activity. b Scatter plot representing the normalized senolytic activity obtained with each compound present in the Prestwick Chemical Library. Proscillaridin A value highlighted in red. c IC50 curves obtained with increasing concentrations of Proscillaridin A, Ouabain and Digoxin (from left to right) in A549 tumor cells (upper panels) and BJ primary fibroblasts (bottom panels). Actual IC50 values and Senolytic Indexes (SI) are also shown for each condition. d Relative cell viability (%) after Digoxin or vehicle treatment of A549 cells rendered senescent by different chemotherapeutic reagents (Bleo: Bleomycin; Gem: Gemcitabine; Doxo: Doxorubicin; Eto: Etoposide; and Palbo: Palbociclib). n = 3 independent experiments. Statistical significance was assessed by the two-tailed Student's t-test: ***p < 0.001. e IC50 curves of BJ primary fibroblasts induced to senescence by oncogenic RAS overexpression (left panel) or H2O2 treatment (right panel) treated with increasing concentrations of Digoxin. f IC50 curves of SK-MEL-103 melanoma cells induced to senescence by Palbociclib and treated with increasing concentrations of the indicated CGs identified on a screening for senolytic activities present in compounds obtained from plant extracts. Data correspond to the average ± s.d. Source data for these experiments are provided as a Source Data file
Fig. 1 High-throughput screenings of senolytic compounds. a Schematic diagram of the experimental system used to screen compounds for potential senolytic activity. b Scatter plot representing the normalized senolytic activity obtained with each compound present in the Prestwick Chemical Library. Proscillaridin A value highlighted in red. c IC50 curves obtained with increasing concentrations of Proscillaridin A, Ouabain and Digoxin (from left to right) in A549 tumor cells (upper panels) and BJ primary fibroblasts (bottom panels). Actual IC50 values and Senolytic Indexes (SI) are also shown for each condition. d Relative cell viability (%) after Digoxin or vehicle treatment of A549 cells rendered senescent by different chemotherapeutic reagents (Bleo: Bleomycin; Gem: Gemcitabine; Doxo: Doxorubicin; Eto: Etoposide; and Palbo: Palbociclib). n = 3 independent experiments. Statistical significance was assessed by the two-tailed Student's t-test: ***p < 0.001. e IC50 curves of BJ primary fibroblasts induced to senescence by oncogenic RAS overexpression (left panel) or H2O2 treatment (right panel) treated with increasing concentrations of Digoxin. f IC50 curves of SK-MEL-103 melanoma cells induced to senescence by Palbociclib and treated with increasing concentrations of the indicated CGs identified on a screening for senolytic activities present in compounds obtained from plant extracts. Data correspond to the average ± s.d. Source data for these experiments are provided as a Source Data fileCC BY · PubMed Central
Fig. 2 CGs kill senescent cells by inducing apoptosis. a Annexin V positive cells (%) in proliferating (Pro, in green) and senescence (Sen, in red) A549 cells (left panel) or primary BJ fibroblasts (right panel) after Digoxin treatment. b Active Caspase-3 positive cells (%) in proliferating (Pro, in green) and senescence (Sen, in red) A549 cells (left panel) or primary BJ fibroblasts (right panel) after Digoxin treatment. c Relative cell viability (%) of proliferative (Pro) or senescence (Sen) A549 cells treated with pan caspase inhibitor Z-VAD-FMK (ZVF), Digoxin (Dig) or the combination, as indicated. n = 3 independent experiments. All data correspond to the average ± s.d. Statistical significance was assessed by the two-tailed Student's t-test: ***p < 0.001; **p < 0.01. Source data for these experiments are provided as a Source Data file
Fig. 2 CGs kill senescent cells by inducing apoptosis. a Annexin V positive cells (%) in proliferating (Pro, in green) and senescence (Sen, in red) A549 cells (left panel) or primary BJ fibroblasts (right panel) after Digoxin treatment. b Active Caspase-3 positive cells (%) in proliferating (Pro, in green) and senescence (Sen, in red) A549 cells (left panel) or primary BJ fibroblasts (right panel) after Digoxin treatment. c Relative cell viability (%) of proliferative (Pro) or senescence (Sen) A549 cells treated with pan caspase inhibitor Z-VAD-FMK (ZVF), Digoxin (Dig) or the combination, as indicated. n = 3 independent experiments. All data correspond to the average ± s.d. Statistical significance was assessed by the two-tailed Student's t-test: ***p < 0.001; **p < 0.01. Source data for these experiments are provided as a Source Data fileCC BY · PubMed Central
Fig. 3 Mechanism of action of Digoxin-induced senolysis. a Diagram showing the activity of Digoxin. b Relative cell viability (%) of proliferative (green) or senescence (red) A549 cells overexpressing human or mouse ATP1A1 or Atp1a1, respectively, and treated with Digoxin or Navitoclax. Statistical analysis with Anova with Tuckey test: ***p < 0.001; *p < 0.05; c and mRNA expression (relative to GAPDH) of ATP1A1 (left) and Atp1a1 (right). n = 3 independent experiments for both d Membrane potential determination of proliferative (green) or senescence (red) A549 cells treated with Digoxin and KCl, using fluorescent probe DiBAC4(3). n = 10 biologically independent samples. Statistical significance by two-tailed Student's t-test: **p < 0.01; *p < 0.05. e Relative cell viability (%) of proliferative (green) or senescence (red) A549 cells treated with Digoxin and KCl. n = 7 biologically independent samples. Statistical analysis with Anova with Tuckey test: **p < 0.01. f Determination of the relative intracellular H+concentration in proliferative (green) or senescence (red) A549 cells treated or not with Digoxin. n = 4 biologically independent samples. Statistical significance by two-tailed Student's t-test: ***p < 0.001. g Relative cell viability (%) of proliferative (green) or senescence (red) A549 cells treated or not with Amiloride. n = 3 biologically independent samples. Statistical significance by two-tailed Student's t-test: ***p < 0.001. h Relative mRNA expression of SLC9A1 in proliferative (green) or senescence (red) A549 cells overexpressing or not SLC9A1 as indicated. n = 3 biologically independent samples. Statistical significance by two-tailed Student's t-test: **p < 0.01; *p < 0.05. i Relative cell viability (%) of proliferative (green) or senescence (red) A549 cells treated with Digoxin and exogenously expressing SLC9A1 or GFP. n = 3 independent experiments. Statistical significance by two-tailed Student's t-test: **p < 0.01; n.s. not significant. All data correspond to the average ± s.d. Source data for these experiments are provided as a Source Data file
Fig. 3 Mechanism of action of Digoxin-induced senolysis. a Diagram showing the activity of Digoxin. b Relative cell viability (%) of proliferative (green) or senescence (red) A549 cells overexpressing human or mouse ATP1A1 or Atp1a1, respectively, and treated with Digoxin or Navitoclax. Statistical analysis with Anova with Tuckey test: ***p < 0.001; *p < 0.05; c and mRNA expression (relative to GAPDH) of ATP1A1 (left) and Atp1a1 (right). n = 3 independent experiments for both d Membrane potential determination of proliferative (green) or senescence (red) A549 cells treated with Digoxin and KCl, using fluorescent probe DiBAC4(3). n = 10 biologically independent samples. Statistical significance by two-tailed Student's t-test: **p < 0.01; *p < 0.05. e Relative cell viability (%) of proliferative (green) or senescence (red) A549 cells treated with Digoxin and KCl. n = 7 biologically independent samples. Statistical analysis with Anova with Tuckey test: **p < 0.01. f Determination of the relative intracellular H+concentration in proliferative (green) or senescence (red) A549 cells treated or not with Digoxin. n = 4 biologically independent samples. Statistical significance by two-tailed Student's t-test: ***p < 0.001. g Relative cell viability (%) of proliferative (green) or senescence (red) A549 cells treated or not with Amiloride. n = 3 biologically independent samples. Statistical significance by two-tailed Student's t-test: ***p < 0.001. h Relative mRNA expression of SLC9A1 in proliferative (green) or senescence (red) A549 cells overexpressing or not SLC9A1 as indicated. n = 3 biologically independent samples. Statistical significance by two-tailed Student's t-test: **p < 0.01; *p < 0.05. i Relative cell viability (%) of proliferative (green) or senescence (red) A549 cells treated with Digoxin and exogenously expressing SLC9A1 or GFP. n = 3 independent experiments. Statistical significance by two-tailed Student's t-test: **p < 0.01; n.s. not significant. All data correspond to the average ± s.d. Source data for these experiments are provided as a Source Data fileCC BY · PubMed Central
Fig. 4 Senolytic activity of Digoxin on xenografts. a Diagram showing the experimental plan to test the effect of administrating Gemcitabine, Digoxin or the combination of both (Gem+Dig) in the growth of A549 cells expressing luciferase (A549-Luc) as subcutaneous tumors in nude mice. b Tumor volume (mm3) progression with time after intraperitoneal injection of Gemcitabine (n = 12), Digoxin (n = 8) or the combination of both (Gem+Dig) (n = 12), or vehicle (n = 4) as negative control as indicated. Statistical analysis was performed with Anova with Tuckey test: ***p < 0.001; **p < 0.01. c Tumor growth determined by measuring normalized total flux of luminescence as detected by IVIS with the same groups of animals. Statistical analysis was performed with Anova with Tuckey test: ***p < 0.001. d Representative images of SABG staining (upper panels) and immunohistochemical analysis of p21 (middle panels) and Ki67 (bottom panels) in tumors obtained after injection of A549 cells in nude mice and treated with Gemcitabine, Gemcitabine plus Digoxin (Gem+Dig), or control group (scale bar = 50 μm). e Quantifications of stainings shown in (d). n = 3 biologically independent samples. Statistical significance was assessed by the two-tailed Student's t-test: ***p < 0.001; **p < 0.01; *p < 0.05. All data correspond to the average ± s.d. Source data for these experiments are provided as a Source Data file
Fig. 4 Senolytic activity of Digoxin on xenografts. a Diagram showing the experimental plan to test the effect of administrating Gemcitabine, Digoxin or the combination of both (Gem+Dig) in the growth of A549 cells expressing luciferase (A549-Luc) as subcutaneous tumors in nude mice. b Tumor volume (mm3) progression with time after intraperitoneal injection of Gemcitabine (n = 12), Digoxin (n = 8) or the combination of both (Gem+Dig) (n = 12), or vehicle (n = 4) as negative control as indicated. Statistical analysis was performed with Anova with Tuckey test: ***p < 0.001; **p < 0.01. c Tumor growth determined by measuring normalized total flux of luminescence as detected by IVIS with the same groups of animals. Statistical analysis was performed with Anova with Tuckey test: ***p < 0.001. d Representative images of SABG staining (upper panels) and immunohistochemical analysis of p21 (middle panels) and Ki67 (bottom panels) in tumors obtained after injection of A549 cells in nude mice and treated with Gemcitabine, Gemcitabine plus Digoxin (Gem+Dig), or control group (scale bar = 50 μm). e Quantifications of stainings shown in (d). n = 3 biologically independent samples. Statistical significance was assessed by the two-tailed Student's t-test: ***p < 0.001; **p < 0.01; *p < 0.05. All data correspond to the average ± s.d. Source data for these experiments are provided as a Source Data fileCC BY · PubMed Central
Fig. 5 Senolytic activity of Digoxin on human PDX. a In vitro SABG staining of PDX375 in control, Doxorubicin, Digoxin and Doxorubicin plus Digoxin (Dox+Dig) treated cells (scale bar = 100 μm). b Representative immunofluorescent images of PDX375 cells transduced with lentiviral reporter constructs for the expression of p21 (in green) and IL6 (in red) in control condition or after Doxorubicin treatment. DAPI (in blue) was used to stained nuclei (scale bar = 100 μm). c Quantification (fold change) of double positive p21/IL6 cells in control, or Doxorubicin (Doxo), Digoxin (Dig), or Doxorubicin plus Digoxin (D+D) treatment (n = 3 biologically independent samples). d In vitro cell viability (relative to control) of PDX375 cells treated with Doxorubicin (Doxo), Digoxin (Dig), or the combination (D+D) (n = 3 biologically independent samples). e In vivo growth (tumor volume) of PDX375 subcutaneously injected into nude mice and treated with Doxorubicin (Doxo: 2 mg/kg; n = 6), Digoxin (Dig: 2 mg/kg; n = 6), the combination (D+D; n = 5), or vehicle (Control; n = 5). f Same in vivo growth analysis in mice treated with Doxorubicin (Doxo: 10 mg/kg; n = 8), Digoxin (Dig: 2 mg/kg; n = 8), the combination (D+D; n = 6), or vehicle (Control; n = 8). Statistical significance was assessed by the two-tailed Student's t-test: ***p < 0.001; **p < 0.01; *p < 0.05. All data correspond to the average ± s.d. Source data for these experiments are provided as a Source Data file
Fig. 5 Senolytic activity of Digoxin on human PDX. a In vitro SABG staining of PDX375 in control, Doxorubicin, Digoxin and Doxorubicin plus Digoxin (Dox+Dig) treated cells (scale bar = 100 μm). b Representative immunofluorescent images of PDX375 cells transduced with lentiviral reporter constructs for the expression of p21 (in green) and IL6 (in red) in control condition or after Doxorubicin treatment. DAPI (in blue) was used to stained nuclei (scale bar = 100 μm). c Quantification (fold change) of double positive p21/IL6 cells in control, or Doxorubicin (Doxo), Digoxin (Dig), or Doxorubicin plus Digoxin (D+D) treatment (n = 3 biologically independent samples). d In vitro cell viability (relative to control) of PDX375 cells treated with Doxorubicin (Doxo), Digoxin (Dig), or the combination (D+D) (n = 3 biologically independent samples). e In vivo growth (tumor volume) of PDX375 subcutaneously injected into nude mice and treated with Doxorubicin (Doxo: 2 mg/kg; n = 6), Digoxin (Dig: 2 mg/kg; n = 6), the combination (D+D; n = 5), or vehicle (Control; n = 5). f Same in vivo growth analysis in mice treated with Doxorubicin (Doxo: 10 mg/kg; n = 8), Digoxin (Dig: 2 mg/kg; n = 8), the combination (D+D; n = 6), or vehicle (Control; n = 8). Statistical significance was assessed by the two-tailed Student's t-test: ***p < 0.001; **p < 0.01; *p < 0.05. All data correspond to the average ± s.d. Source data for these experiments are provided as a Source Data fileCC BY · PubMed Central
Fig. 6 Senolytic activity of Digoxin in lung fibrosis. a Schematic diagram of the experimental system to induce lung fibrosis in mice by intratracheal instillation of proliferative or senescent gamma-irradiated IMR90 cells. b In vitro SABG staining of control or gamma-irradiated (g-IR) IMR90 cells (scale bar = 100 μm). c In vitro analysis of cell death in control or (g-IR) IMR90 cells treated or not with Digoxin (Dig). Black bars represent the % of DiOC6(3) low and grey bars represent Hoechst 33342 positive cells. n = 3 independent experiments. d Relative expression of the mRNA coding for CDKN2A (left panel) or Cdkn2a (right panel) in lung cell extracts from mice injected with control proliferative (green) or gamma-irradiated (g-IR, red) IMR90 cells, and treated or not with Digoxin, as indicated. n = 5 independent experiments. e Representative images of lung sections stained with Masson Trichrome from mice injected with gamma-irradiated IMR90 cells and treated (bottom panel) or not (upper panel) with Digoxin (scale bar = 100 μm). f Ashcroft score of Masson Trichrome staining in sections from mice injected with control proliferative or gamma-irradiated (g-IR) IMR90 cells, treated or not with Digoxin (+Dig). n = 5 independent experiments. Statistical significance was assessed by the two-tailed Student's t-test: ***p < 0.001; **p < 0.01; *p < 0.05. Data correspond to the average ± s.d. Source data for these experiments are provided as a Source Data file
Fig. 6 Senolytic activity of Digoxin in lung fibrosis. a Schematic diagram of the experimental system to induce lung fibrosis in mice by intratracheal instillation of proliferative or senescent gamma-irradiated IMR90 cells. b In vitro SABG staining of control or gamma-irradiated (g-IR) IMR90 cells (scale bar = 100 μm). c In vitro analysis of cell death in control or (g-IR) IMR90 cells treated or not with Digoxin (Dig). Black bars represent the % of DiOC6(3) low and grey bars represent Hoechst 33342 positive cells. n = 3 independent experiments. d Relative expression of the mRNA coding for CDKN2A (left panel) or Cdkn2a (right panel) in lung cell extracts from mice injected with control proliferative (green) or gamma-irradiated (g-IR, red) IMR90 cells, and treated or not with Digoxin, as indicated. n = 5 independent experiments. e Representative images of lung sections stained with Masson Trichrome from mice injected with gamma-irradiated IMR90 cells and treated (bottom panel) or not (upper panel) with Digoxin (scale bar = 100 μm). f Ashcroft score of Masson Trichrome staining in sections from mice injected with control proliferative or gamma-irradiated (g-IR) IMR90 cells, treated or not with Digoxin (+Dig). n = 5 independent experiments. Statistical significance was assessed by the two-tailed Student's t-test: ***p < 0.001; **p < 0.01; *p < 0.05. Data correspond to the average ± s.d. Source data for these experiments are provided as a Source Data fileCC BY · PubMed Central

Verification

Claims the paper makes

6 Valid · 2 Not valid · 14 Not checked · 99 Own results and interpretations

75 more claims

Create a free account to see all 121 claims and to verify the 20 references still open.

See all claims — free account
  • Probably not a substantial claim. 22
  • It may state two separate claims as one. 21

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

5 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 59 references

Cited by

See all 391

Metadata

Authors
Triana-Martínez, F., Picallos-Rabina, P., Da Silva-Álvarez, S., Pietrocola, F., Llanos, S., Rodilla, V., Soprano, E., Pedrosa, P., Ferreirós, A., Barradas, M., Hernández-González, F., Lalinde, M., Prats, N., Bernadó, C., González, P., Gómez, M., Ikonomopoulou, M. P., Fernández-Marcos, P. J., García-Caballero, T., del Pino, P., Arribas, J., Vidal, A., González-Barcia, M., Serrano, M., Loza, M. I., Domínguez, E., & Collado, M.
Affiliations
  • Universidade de Santiago de Compostela (ES)
  • Instituto de Investigación Sanitaria de Santiago (ES)
  • Institute for Research in Biomedicine (ES)
  • Spanish National Cancer Research Centre (ES)
  • Centro de Investigación Biomédica en Red de Cáncer (ES)
  • Madrid Institute for Advanced Studies (ES)
  • Institució Catalana de Recerca i Estudis Avançats (ES)
Corresponding author
  • Domínguez, Eduardo
  • Collado, Manuel
Venue
Nature Communications
Published
2019-10-21
Volume
10
Issue
1
Pages
4731-4731
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2981220896
Cited by
384
References
59
Citations by year
2026: 33 · 2025: 57 · 2024: 67 · 2023: 62 · 2022: 54 · 2021: 53 · 2020: 54 · 2019: 4
FWCI
28.30
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by-nc-sa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • Hispana (submittedVersion, cc-by)
  • RUNA. Repositorio Institucional del Sergas (Servicio Gallego de Salud (SERGAS)) (submittedVersion, cc-by)
Funders
  • Fundación Ramón Areces (CIVP18A3891)
  • Ministerio de Ciencia, Innovación y Universidades (RTI2018-095818-B-100, RYC-2017, RTI2018)
  • Consejo Nacional de Ciencia y Tecnología
  • Ministerio de Ciencia e Innovación (RYC-2017-22335, RYC 2017)
  • Xunta de Galicia
  • European Regional Development Fund (RYC-2017-22335, SAF2013-48256-R, RTI2018, ERC-2014- AdG/669622)
  • Agencia Estatal de Investigación
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
  • Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
Keywords
cardiac glycosides, senolytics, cellular senescence, Na+/K+-ATPase, membrane depolarization, intracellular acidification, senolytic therapy, age-related diseases, tumor xenografts
MeSH terms
A549 Cells, Animals, Antibiotics, Antineoplastic, Bleomycin, Breast Neoplasms, Cardiac Glycosides, Cell Membrane, Digoxin, Female, Fibroblasts, Humans, Hydrogen-Ion Concentration, Osteoarthritis, Ouabain, Proscillaridin, Pulmonary Fibrosis, Cellular Senescence, Apoptosis, Chondrocytes, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Identification and characterization of Cardiac Glycosides as senolytic compounds. https://app.cochat.ai/papers/10.1038/s41467-019-12888-x
The paper
Triana-Martínez, F., Picallos-Rabina, P., Da Silva-Álvarez, S., Pietrocola, F., Llanos, S., Rodilla, V., Soprano, E., Pedrosa, P., Ferreirós, A., Barradas, M., Hernández-González, F., Lalinde, M., Prats, N., Bernadó, C., González, P., Gómez, M., Ikonomopoulou, M. P., Fernández-Marcos, P. J., García-Caballero, T., . . . Collado, M. (2019). Identification and characterization of Cardiac Glycosides as senolytic compounds. Nature Communications. https://doi.org/10.1038/s41467-019-12888-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.